Az Üzleti Sajtószolgálat (Original Text Service - OTS) üzleti vállakozások, cégek, intézmények közleményeit, tájékoztatóit, meghívóit, állásfoglalásait közli. Szolgáltatásunk segítségével több mint 2000 újságírót és kommunikációs szakembert érhet el könnyen, gyorsan és költséghatékonyan – az Ön által megfogalmazott sajtóközleményt változtatás nélkül juttatjuk el az MTI-előfizetők szerkesztőségi rendszerébe vagy igény szerint akár a külföldi sajtóhoz is. (Az OTS anyagai nem képezik az MTI-kiadás részét, a szó szerint továbbított szövegekért minden esetben a közlő a felelős.)
|
|
|
2022. szeptember 13., kedd 16:00 |
Debiopharm Co-leads a 10M USD Series A Round to Accelerate the Development of Genomic Medicines through Artificial Intelligence |
|
Lausanne, Switzerland, 13 September, 2022 (APA/OTS) - Debiopharm Innovation Fund strategically invests in Whitelab Genomics' mission to make genomic medicine development faster and leaner for more efficient access to cancer patients in the future |
Debiopharm Innovation Fund, the strategic investment arm of Swiss
biopharmaceutical company Debiopharm (www.Debiopharm.com), announced
today their investment in Whitelab Genomics alongside French Venture
Capital company, Omnes Capital, in a $10 Million Series A Round to
advance their mission to accelerate the development of genomics
medicines via technology powered by artificial intelligence (AI).
Whitelab Genomics' computational platform reduces biotherapies'
development time and cost, enabling faster access to the market and
cheaper therapeutic solutions available for patients in need.
Debiopharm's investment in Whitelabs Genomics contributes to the
growth plan of the start-up' R&D team and US operations. Such an
investment aligns with Debiopharm's focus on investing in digital
health solutions that improve the cancer patient journey, transform
pharmaceutical R&D, and shift healthcare towards a more
patient-centric approach.
Founded in 2019 by David Del Bourgo, MBA, and Julien Cottineau,
Ph.D., alongside a team of world-class data scientists specialized
in AI, computational biologists, molecular biologists, and genomic
medicine scientists, the start-up offers in-silico simulations
customized for target discovery, vector, and payload design,
genotoxicity assessment and identification of experimental protocols
of in vitro and in vivo strategies.
"We're moving into a time where AI-based technology will play a
critical role in drug development. With better ways to develop
drugs, de-risk assets, de-risk any toxicity, and ensure efficacy,
we're able to bring more personalized drugs to patients - that's
precisely what Whitelab Genomics is proven to do," stated Tanja
Dowe, CEO of the Debiopharm Innovation Fund.
"The value of using this AI-based platform is the potential
acceleration of pre-clinical, translational stage, helping drug
research companies quickly design payloads and vectors and identify
the best experimental protocols for in vitro and in vivo tests,"
said Hamzeh Abdul-Hadi, Investment Director of the Debiopharm
Innovation Fund.
"We are very excited to close this first institutional investment
round with such renowned investors with deep knowledge of the pharma
environment. With this funding, we can continue developing our
proprietary data sets and algorithms for both payload and vectors,
and develop our collaborations with our customers," expressed David
Del Bourgo, CEO and co-founder of Whitelab Genomics.
About Whitelab Genomics WhiteLab Genomics, based in Paris and Cambridge (MA) was founded in
2019 by David Del Bourgo and Julien Cottineau, experts in genomics
drug development and commercialization. WhiteLab Genomics aims to
revolutionize genomic therapies development using public and private
data and in-house AI algorithms. Whitelab Genomics supports its
clients through the in-silico development phases enabling them to
quickly develop target vectors and payloads and save precious time
needed to give patients access to new genomic therapies. In only 2
years, Whitelab Genomics has convinced leading European and US
Biotech and pharma to use its solutions for their new drug
development programs, including RNA, DNA & Cell therapies. WhiteLab
Genomics is also collaborating with world-renowned INSERM and
Genethon laboratories and has been selected by Y-Combinator in its
Winter 2022 batch. The company has won multiple awards, including
the Galien Foundation nominee for startups, the Alumni New Venture
Fund from the Polsky Innovation Center at the University of Chicago,
and the Future 40 from Station F. For more information, please visit www.whitelabgx.com
About Debiopharm Innovation Fund Debiopharm Innovation Fund, the strategic investment arm of Swiss
biopharmaceutical company Debiopharm, provides strategic funding and
guidance for companies with an ambition to improve the patient
journey, re-imagine how clinical trials are conducted, along with
companies offering digital platforms that support cutting-edge drug
technologies. Since 2017 Debiopharm has invested in 14 digital
health companies, typically leading the investment rounds. For more information, please visit
www.debiopharm.com/digital-health/ We are on Twitter. Follow us @DebiopharmNews at
http://twitter.com/DebiopharmNews
Debiopharm Contact Dawn Bonine Head of Communications dawn.bonine@debiopharm.com Tel: +41 (0)21 321 01 11
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók
a forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI
által szó szerint továbbított tartalomért minden esetben a beadó a
felelős. © Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.
|
|
|
|
|
|
|
|
|
|
|